US Stock MarketDetailed Quotes
AKBA Akebia Therapeutics
- 1.3700
- +0.0700+5.38%
Close May 3 16:00 ET
- 1.4400
- +0.0700+5.11%
Post 19:49 ET
287.15MMarket Cap-4892P/E (TTM)
1.4200High1.3200Low3.12MVolume1.3400Open1.3000Pre Close4.30MTurnover1.64%Turnover RatioLossP/E (Static)209.60MShares2.480052wk High-9.38P/B260.88MFloat Cap0.780152wk Low--Dividend TTM190.42MShs Float31.0000Historical High--Div YieldTTM7.69%Amplitude0.2410Historical Low1.3790Avg Price1Lot Size
Akebia Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 68.03%-23.38M | 95.78%-2.31M | -121.20%-7.17M | 111.84%3.63M | 18.88%-17.54M | 71.08%-73.15M | 12.94%-54.68M | 160.08%33.81M | 51.44%-30.66M | 69.44%-21.62M |
| Net income from continuing operations | 44.89%-51.93M | 110.11%614K | 73.22%-14.49M | -141.72%-11.83M | 58.00%-26.22M | 66.59%-94.23M | 91.31%-6.07M | 9.15%-54.1M | 134.16%28.36M | 10.29%-62.42M |
| Operating gains losses | -16.21%-760K | ---- | ---- | ---- | ---- | -9.00%-654K | --0 | --56K | --0 | -987.50%-710K |
| Depreciation and amortization | 18.61%41.85M | 68.30%14.84M | 3.83%9.14M | 2.79%9.03M | -0.45%8.83M | -2.35%35.28M | -2.28%8.82M | -2.55%8.8M | -2.80%8.79M | -1.76%8.87M |
| Other non cash items | 95.49%-2.72M | 96.59%-2.57M | -101.00%-152K | 46.73%-855K | -42.31%859K | -251.27%-60.2M | -537.45%-75.31M | 522.24%15.23M | -104.90%-1.61M | 122.65%1.49M |
| Change In working capital | -1,336.38%-20.73M | -200.28%-16.21M | -107.27%-4.21M | 104.68%3.52M | -118.03%-3.84M | 98.63%-1.44M | 82.94%-5.4M | 712.71%57.89M | -166.75%-75.21M | 158.54%21.27M |
| -Change in receivables | -91.20%994K | 1.86%-16.7M | -105.14%-3.02M | 95.89%-687K | 256.12%21.4M | 147.02%11.3M | -1,329.83%-17.02M | 499.95%58.73M | -7,430.70%-16.71M | -63.57%-13.71M |
| -Change in inventory | -113.32%-2.54M | -148.18%-11.78M | -58.52%-1.59M | 293.33%3.48M | 240.02%7.35M | 176.51%19.09M | 136.59%24.45M | -334.35%-1M | 105.36%885K | 72.66%-5.25M |
| -Change in prepaid assets | 1,019.00%11.84M | 120.55%1.8M | -74.46%2.36M | 103.62%306K | -18.19%7.38M | 105.67%1.06M | -237.38%-8.74M | 132.62%9.24M | -918.78%-8.46M | 297.66%9.02M |
| -Change in payables and accrued expense | 58.18%-15.27M | 235.39%8.22M | 174.49%7.96M | 110.34%2.62M | -1,061.66%-34.06M | -7.95%-36.5M | 107.21%2.45M | -162.87%-10.68M | -260.08%-25.34M | 70.05%-2.93M |
| -Change in other current assets | 75.80%-1.36M | 125.56%6.81M | -120.86%-2.3M | -145.63%-3.06M | -185.29%-2.81M | 31.54%-5.62M | -105.95%-26.65M | 1,803.11%11.02M | 140.85%6.72M | 142.25%3.3M |
| -Change in other current liabilities | -332.21%-10.65M | -125.83%-4.56M | -35.19%-7.61M | 117.84%864K | 125.28%651K | 105.83%4.59M | 1,570.17%17.64M | -1,626.29%-5.63M | -1,319.65%-4.84M | -732.68%-2.58M |
| -Change in other working capital | -180.32%-3.74M | --0 | --0 | --0 | -111.19%-3.74M | 155.57%4.65M | 293.66%2.47M | -124.90%-3.78M | -202.18%-27.45M | 1,211.27%33.42M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 68.03%-23.38M | 95.78%-2.31M | -121.20%-7.17M | 111.84%3.63M | 18.88%-17.54M | 71.08%-73.15M | 12.94%-54.68M | 160.08%33.81M | 51.44%-30.66M | 69.44%-21.62M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 0 | 0 | 0 | 0 | 0 | -100.29%-114K | 0 | 0 | 0 | -100.57%-114K |
| Net PPE purchase and sale | --0 | --0 | --0 | --0 | --0 | -93.22%-114K | --0 | --0 | --0 | -93.22%-114K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | --0 | --0 | --0 | --0 | --0 | -100.29%-114K | --0 | --0 | --0 | -100.57%-114K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -272.67%-25.21M | -128,900.00%-1.29M | 100.15%50K | -88,788.89%-8M | -133.58%-15.97M | -89.08%14.6M | -100.02%-1K | -299.84%-32.94M | -100.02%-9K | -36.16%47.55M |
| Net issuance payments of debt | 3.03%-32M | ---8M | --0 | ---8M | ---16M | ---33M | --0 | ---33M | --0 | --0 |
| Net common stock issuance | -5.80%6.71M | 670,900.00%6.71M | --0 | --0 | --0 | -91.93%7.12M | -100.02%-1K | -99.88%20K | -100.20%-76K | -75.52%7.18M |
| Proceeds from stock option exercised by employees | -81.97%86K | --2K | 16.28%50K | --0 | -90.74%34K | -36.06%477K | --0 | -88.65%43K | --67K | 0.00%367K |
| Net other financing activities | ---- | ---- | ---- | ---- | ---- | -10.68%40M | --0 | --0 | --0 | -10.68%40M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -272.67%-25.21M | -128,900.00%-1.29M | 100.15%50K | -88,788.89%-8M | -133.58%-15.97M | -89.08%14.6M | -100.02%-1K | -299.84%-32.94M | -100.02%-9K | -36.16%47.55M |
| Net cash flow | ||||||||||
| Beginning cash position | -38.64%93.17M | -67.41%48.18M | -62.38%55.29M | -66.41%59.67M | -38.64%93.17M | -34.31%151.84M | -29.34%147.85M | -40.98%146.98M | -30.28%177.65M | -34.31%151.84M |
| Current changes in cash | 17.18%-48.59M | 93.42%-3.6M | -919.93%-7.12M | 85.75%-4.37M | -229.81%-33.5M | 26.01%-58.67M | 4.75%-54.68M | 102.18%868K | -431.34%-30.67M | 9.04%25.81M |
| End cash Position | -52.15%44.58M | -52.15%44.58M | -67.41%48.18M | -62.38%55.29M | -66.41%59.67M | -38.64%93.17M | -38.64%93.17M | -29.34%147.85M | -40.98%146.98M | -30.28%177.65M |
| Free cash flow | 68.08%-23.38M | 95.78%-2.31M | -121.20%-7.17M | 111.84%3.63M | 19.31%-17.54M | 71.04%-73.27M | 12.94%-54.68M | 160.08%33.81M | 51.44%-30.66M | 69.30%-21.73M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg